drugset / Trial / NCT07005180
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
Phase 2
Recruiting
36 enrolled
Hillhurst Biopharmaceuticals, Inc.
The Parkinson Study Group · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).
Timeline
- Start
- 2026-05-15
- Primary completion
- 2026-12-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HBI-002 | Unknown | — | Oral |